Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Denosumab Does Not Stimulate Early Bone Formation

Reuters Staff  |  

Eli Lilly and Company, which manufactures teriparatide, sponsored the trial, employed five of the 15 authors, and had various relationships with all but one of the others.

Dr. Dempster did not respond to a request for comments.

ADVERTISEMENT
SCROLL TO CONTINUE

Related Articles

    Teriparatide to Denosumab Switch Helpful in Osteoporosis

    NEW YORK (Reuters Health)—In postmenopausal osteoporotic women, changing from teriparatide to denosumab benefits bone mineral density (BMD) but switching from denosumab to teriparatide may result in bone loss, according to new research. In a July 3 online paper in The Lancet, Dr. Benjamin Z. Leder, of Massachusetts General Hospital, Boston, and colleagues noted that many…